Abemaciclib Clinical Trials
65 recruitingDrug
Phase 248Phase 129Phase 37Phase 41
Showing 1–20 of 65 trials
Recruiting
Phase 1Phase 2
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Castration-Resistant Prostate CarcinomaStage IV Prostate Cancer AJCC v8Metastatic Castration-resistant Prostate Cancer+4 more
Vadim S Koshkin30 enrolled1 locationNCT05113537
Recruiting
Phase 3
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
HR+/HER2- Breast Cancer
BeOne Medicines1,056 enrolled74 locationsNCT07492641
Recruiting
Phase 1
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Breast Cancer
Eli Lilly and Company260 enrolled50 locationsNCT05307705
Recruiting
Phase 2
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
NeoplasmsAdolescentChild
Eli Lilly and Company105 enrolled73 locationsNCT05999994
Recruiting
Phase 2
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Recurrent Ovarian CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube Carcinoma+1 more
Jonsson Comprehensive Cancer Center32 enrolled1 locationNCT04469764
Recruiting
Phase 1Phase 2
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
Neurofibromatosis 1
National Cancer Institute (NCI)55 enrolled1 locationNCT04750928
Recruiting
Phase 2
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Endometrial Cancer
Memorial Sloan Kettering Cancer Center75 enrolled7 locationsNCT07209449
Recruiting
Phase 1Phase 2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Metastatic Breast Cancer
Hoffmann-La Roche1,132 enrolled47 locationsNCT03424005
Recruiting
Phase 1Phase 2
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Breast Cancer
Genentech, Inc.285 enrolled52 locationsNCT07100106
Recruiting
Phase 1
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Recurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Platinum-Resistant Ovarian Carcinoma
National Cancer Institute (NCI)42 enrolled27 locationsNCT04633239
Recruiting
Phase 4
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
Breast Cancer
University of Illinois at Chicago50 enrolled3 locationsNCT06169371
Recruiting
Phase 1Phase 2
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Breast CancerSolid Tumors, Adult
Eli Lilly and Company880 enrolled65 locationsNCT05768139
Recruiting
Phase 3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company920 enrolled338 locationsNCT07174336
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled352 locationsNCT06065748
Recruiting
Phase 1Phase 2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Hoffmann-La Roche316 enrolled32 locationsNCT04802759
Recruiting
Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation
Alliance for Clinical Trials in Oncology124 enrolled780 locationsNCT02523014
Recruiting
Phase 3
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Advanced Breast Cancer
AstraZeneca500 enrolled301 locationsNCT06380751
Recruiting
Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca895 enrolled284 locationsNCT04862663
Recruiting
Phase 1Phase 2
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
Adenoid Cystic CarcinomaMetastatic Adenoid Cystic CarcinomaRecurrent Adenoid Cystic Carcinoma
Glenn J. Hanna32 enrolled1 locationNCT05774899
Recruiting
Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Breast Cancer (Early Breast Cancer)
AstraZeneca5,500 enrolled798 locationsNCT05952557